Biotech | May 11, 2022
New nirsevimab data analyses reinforce efficacy against RSV
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
The research was funded by the National Institutes of Health, the Eversight Center for Vision and Eye Banking Research, and Research to Prevent Blindness
The announcement follows FDA 510(k) clearance of device
The USFDA approval in AS marks the fifth indication for Rinvoq in chronic immune-mediated diseases
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
It affects up to 10 per cent of women of reproductive age around the world
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
Subscribe To Our Newsletter & Stay Updated
